Structure Therapeutics (NASDAQ:GPCR) Trading Up 6.2% – Should You Buy?

Structure Therapeutics Inc. (NASDAQ:GPCR) was up 6.2% during trading on Friday . The stock traded as high as $24.84 and last traded at $24.84. Approximately 320,756 shares traded hands during mid-day trading, a decline of 58% from the average daily volume of 772,438 shares. The stock had previously closed at $23.39.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reissued a “market outperform” rating and set a $91.00 target price on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $50.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Performance

The firm has a market cap of $1.36 billion, a PE ratio of -32.61 and a beta of -2.75. The firm has a fifty day simple moving average of $27.52 and a two-hundred day simple moving average of $34.11.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its holdings in Structure Therapeutics by 0.7% during the 3rd quarter. Geode Capital Management LLC now owns 45,225 shares of the company’s stock valued at $1,985,000 after buying an additional 312 shares in the last quarter. Virtus ETF Advisers LLC boosted its holdings in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock worth $61,000 after purchasing an additional 455 shares during the period. ANTIPODES PARTNERS Ltd boosted its holdings in shares of Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after purchasing an additional 553 shares during the period. LPL Financial LLC boosted its holdings in shares of Structure Therapeutics by 6.0% in the 4th quarter. LPL Financial LLC now owns 11,485 shares of the company’s stock worth $311,000 after purchasing an additional 646 shares during the period. Finally, Assetmark Inc. boosted its holdings in shares of Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after purchasing an additional 719 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.